For interests sake NYC is around is 40 km across.
The offices of 'Van Leeuwenhoeck' & EAS are approx. 1.6 km apart as the crow flies. Given the relatively higher PE's in the US Bio/Pharma sector and the current traded discount to fair value, opening up Advangen to US investors would offer some massive upside for those in early (and EAS is skilled at getting into mispriced companies early - FMG for example)
For mine it's quite probable that we will see an NYSE Advangen listing. This would tie in with the recent company split.
